ARATANA THERAPEUTICS, INC. PETX Cash Flow

Aratana therapeutics, inc. (PETX)

CashFlow / TTM

Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities
Net loss
-12,961	-14,722	-21,686	-39,439	-43,446	-47,510	-55,245	-59,696	-28,120	-33,575	0	0	0	-	-	-	0	-	-	-	-
Net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,157	0	0	0
Stock-based compensation expense
5,835	4,913	5,496	6,101	6,688	7,118	7,397	7,685	8,037	8,476	8,639	8,652	8,485	8,592	8,378	7,819	7,257	7,130	0	0	0
Depreciation and amortization expense
1,002	990	977	1,053	1,019	1,162	1,181	1,103	1,139	991	982	1,277	1,564	1,840	1,755	1,916	1,997	2,043	0	0	0
Gain on sale of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	3,874	0	0	0	-	-	-	-
Non-cash interest expense
-	1,018	561	554	533	512	489	476	477	478	457	348	239	129	41	41	41	41	0	0	0
Change in fair value of contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-1,248	-1,198	-1,231	-1,397	-133	0	0	0
Change in fair value of derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	1,274	1,941	1,958	1,670	465	0	0	0
Deferred tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-1,698	-1,269	-1,112	-1,087	-1,443	0	0	0
Changes in operating assets and liabilities:
Accounts receivable, net
2,421	-202	10,141	-2,058	-1,101	2,319	9,421	4,876	3,528	27	-118	-130	-103	-281	68	-208	0	102	0	0	0
Inventories
-474	499	6,256	9,311	5,638	3,187	7,494	8,029	11,888	15,010	5,954	3,236	1,708	879	970	758	520	372	0	0	0
Prepaid expenses and other current assets
-104	185	-54	-5,631	11	-335	-355	5,252	-341	771	0	0	0	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Other assets
-269	-188	0	-65	-65	-88	-82	-11	-11	5	0	0	0	-	-	-	-	45	0	0	0
Accounts payable
-921	-6,540	-2,699	-708	723	62	-1,563	-5,227	-5,018	6,182	3,869	5,544	4,231	-117	-654	746	772	-1,143	0	0	0
Accrued expenses and other liabilities
1,753	924	1,286	-2,163	-2,156	-2,605	209	751	2,345	2,084	169	1,206	-288	1,185	864	1,335	909	482	0	0	0
Net cash used in operating activities
-3,538	-11,261	-23,425	-27,665	-32,963	-38,185	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	0	-42,898	-	-37,532	-34,050	-32,983	-32,188	0	0	0
Cash flows from investing activities
Purchase of investments
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of investments
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Milestone payments for intangible assets
-	-	-	-	-	6,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment, net
-	-	-	-	-	-	-	-	-	72	414	1,166	2,202	2,245	1,693	1,323	453	471	0	0	0
Cash paid for acquisitions, net of cash received
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,075	0	0	0
Proceeds from sales of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	7,456	0	0	0	-	-	-	-
Purchase of investments
-	-	-	-	-	3,731	3,980	4,478	33,931	229,836	686,687	1,372,940	2,053,993	2,050,594	1,903,996	1,275,249	563,249	371,449	0	0	0
Proceeds from maturities of investments
-	-	-	-	-	3,980	3,980	3,731	92,436	288,287	744,440	1,443,193	2,052,243	2,079,396	1,896,219	1,206,702	509,194	286,670	0	0	0
Net cash provided by investing activities
2	-493	-3,227	-2,240	-3,005	-5,752	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	643	0	0	0
Purchase of in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,157	0	0	0
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	0	1,654	-	-3,014	-63,414	-54,289	-100,125	0	0	0
Cash flows from financing activities
Taxes paid for awards vested under equity incentive plans
176	68	63	54	50	19	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,081	0	0	0
Proceeds from stock option exercises
37	15	102	107	246	247	0	0	0	-	-	-	-	-	-	-	-	225	0	0	0
Proceeds from issuance of common stock, net of commissions and underwriter fees
-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from public offering, net of commission
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Payments for common stock issuance costs
-	171	164	143	335	345	0	0	0	-	-	-	-	-	-	-	-	2,153	0	0	0
Payments on loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-18,067	0	0	0
Cash paid for contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	3,000	3,000	3,000	3,156	15,166	0	0	0
Payments on loans payable
-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,675	41,794	40,695	100,978	0	0	0
Net cash provided by (used in) financing activities
-26,316	-13,673	12,104	10,378	34,840	23,471	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate on cash
-	-9	-15	-6	26	27	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate on cash
-	-	-	-	-	-	-	-	-	-	32	-16	-1	-131	-44	-10	-2	74	0	0	0
Net decrease in cash, cash equivalents and restricted cash
-29,865	-25,436	-14,563	-19,533	-1,102	-20,439	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	0	0	-16,350	-	-43,265	-55,680	-46,579	-31,261	0	0	0
Supplemental disclosure of cash flow information
Cash paid for interest
-	3,965	2,740	2,876	2,961	2,966	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	1,572	-	986	944	762	942	0	0	0
Supplemental disclosure of noncash investing and financing activities:
Unpaid common stock issuance costs included in accounts payable
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Milestone capitalized as an intangible asset included in accounts payable
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-